Free Trial

Neurocrine Biosciences (NBIX) Competitors

$140.53
+0.02 (+0.01%)
(As of 12:10 PM ET)

NBIX vs. RGEN, EXEL, HALO, DNLI, ADPT, BIIB, TECH, QGEN, PCVX, and ARGX

Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), and argenx (ARGX). These companies are all part of the "biological products, except diagnostic" industry.

Neurocrine Biosciences vs.

Neurocrine Biosciences (NASDAQ:NBIX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Neurocrine Biosciences presently has a consensus price target of $148.96, indicating a potential upside of 5.14%. Repligen has a consensus price target of $197.75, indicating a potential upside of 24.96%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.79
Repligen
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Neurocrine Biosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Neurocrine Biosciences received 582 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 77.58% of users gave Neurocrine Biosciences an outperform vote while only 68.08% of users gave Repligen an outperform vote.

CompanyUnderperformOutperform
Neurocrine BiosciencesOutperform Votes
983
77.58%
Underperform Votes
284
22.42%
RepligenOutperform Votes
401
68.08%
Underperform Votes
188
31.92%

Neurocrine Biosciences has higher revenue and earnings than Repligen. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$1.89B7.49$249.70M$3.6338.71
Repligen$638.76M13.84$41.58M$0.25633.03

Neurocrine Biosciences has a net margin of 18.65% compared to Repligen's net margin of 2.44%. Neurocrine Biosciences' return on equity of 17.45% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences18.65% 17.45% 12.14%
Repligen 2.44%3.95%2.90%

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Neurocrine Biosciences and Neurocrine Biosciences both had 14 articles in the media. Repligen's average media sentiment score of 0.84 beat Neurocrine Biosciences' score of 0.84 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
10 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Repligen
8 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Neurocrine Biosciences beats Repligen on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBIX vs. The Competition

MetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$14.14B$2.92B$5.00B$8.05B
Dividend YieldN/A2.19%2.81%3.93%
P/E Ratio38.7113.98133.4015.40
Price / Sales7.49309.092,452.2675.54
Price / Cash54.06168.4235.9531.61
Price / Book5.936.935.434.60
Net Income$249.70M-$45.88M$104.34M$213.88M
7 Day Performance-1.24%-2.33%-1.47%-1.28%
1 Month Performance1.12%6.18%2.64%2.96%
1 Year Performance51.74%2.62%3.36%7.62%

Neurocrine Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGEN
Repligen
4.4862 of 5 stars
$172.48
+5.6%
$197.75
+14.7%
-6.6%$9.64B$638.76M689.951,783Insider Selling
Analyst Revision
News Coverage
EXEL
Exelixis
4.9867 of 5 stars
$20.99
-1.3%
$26.13
+24.5%
+5.6%$6.36B$1.83B32.801,310Insider Selling
HALO
Halozyme Therapeutics
4.6602 of 5 stars
$43.82
+0.5%
$53.14
+21.3%
+29.1%$5.58B$829.25M18.11373Analyst Forecast
Insider Selling
DNLI
Denali Therapeutics
4.2392 of 5 stars
$19.75
+2.3%
$40.22
+103.7%
-39.7%$2.82B$295.39M-20.57445Positive News
ADPT
Adaptive Biotechnologies
3.7697 of 5 stars
$3.96
+4.2%
$6.80
+71.7%
-47.2%$583.58M$174.50M-2.66709Gap Up
BIIB
Biogen
4.9097 of 5 stars
$226.88
+0.7%
$288.46
+27.1%
-28.1%$33.03B$9.84B28.327,570Analyst Forecast
TECH
Bio-Techne
4.1 of 5 stars
$84.15
+2.7%
$80.50
-4.3%
-3.4%$13.26B$1.14B66.793,050Analyst Downgrade
QGEN
Qiagen
4.1977 of 5 stars
$45.39
+2.4%
$50.95
+12.2%
-8.8%$10.12B$1.94B30.445,967Analyst Revision
PCVX
Vaxcyte
0.6847 of 5 stars
$67.33
+2.5%
$78.50
+16.6%
+37.2%$7.32BN/A-15.73254Insider Selling
ARGX
argenx
2.9647 of 5 stars
$356.01
-1.0%
$524.68
+47.4%
-12.7%$21.16B$1.27B-62.901,148Positive News

Related Companies and Tools

This page (NASDAQ:NBIX) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners